Compare PCLA & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCLA | ABP |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 18.8M |
| IPO Year | 2025 | N/A |
| Metric | PCLA | ABP |
|---|---|---|
| Price | $0.21 | $5.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 748.5K | 28.9K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,065,197.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.26 | ★ 50.00 |
| 52 Week Low | $0.25 | $4.55 |
| 52 Week High | $9.80 | $153.90 |
| Indicator | PCLA | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 19.99 | 55.40 |
| Support Level | $0.27 | $5.55 |
| Resistance Level | $0.33 | $6.38 |
| Average True Range (ATR) | 0.02 | 0.55 |
| MACD | -0.00 | -0.26 |
| Stochastic Oscillator | 7.00 | 32.25 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.